About Prelude Therapeutics Inc
- Industry: Biotechnology
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://preludetx.com/
Frequently Asked Questions
What is the 52-week range for PRLD?
The 52-week high is $6.83 and the 52-week low is $1.15.
What is the P/E ratio for PRLD?
The P/E ratio data is currently unavailable.
What is the dividend yield for PRLD?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is -75.35%.
What is the Net Profit Margin?
The Net Profit Margin (TTM) is -269.75%.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 2.39.
Analyst Recommendation Trends
Wall Street analyst consensus for PRLD over the last few months:
Latest PRLD News
JP Morgan Initiates Coverage On Prelude Therapeutics with Overweight Rating, Announces Price Target of $12
JP Morgan analyst Joyce Zhou initiates coverage on Prelude Therapeutics (NASDAQ:PRLD) with a Overweight rating and announces Price Target of $12.
Prelude Therapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
WILMINGTON, Del., Sept. 11, 2026 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, announced today that the Company will participate in the H.C. Wainwright 28th Annual Global Investment Conference, taking place in New York City September 14-16, 2026. On Wednesday, September 16, 2026, at 10:30 a.m. ET, Kris Vaddi, Ph.D., Chief Executive Officer of Prelude, Charles Morris, MBChB, MRCP. Chief Medical Officer, Peggy Scherle,
Prelude Therapeutics Receives FDA Clearance of Investigational New Drug (IND) Application for PRT13722, Its First-in-Class Oral KAT6A Selective Degrader
Phase 1 study of PRT13722 in patients with HR+ breast cancer anticipated to begin enrolling patients in the fourth quarter of 2026.WILMINGTON, Del., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a precision oncology company, today announced that the U.S. Food and Drug Administration (FDA) cleared the Company to proceed with a Phase 1 study under its Investigational New Drug Application (IND) for PRT13722, an oral KAT6A selective degrader being developed for
Prelude Therapeutics Receives FDA Clearance To Proceed With A Phase 1 Study Under Its Investigational New Drug Application For PRT13722 For The Treatment Of Patients With HR+/HER2- Breast Cancer; Expects To Begin Enrolling Patients In Q4 2026
"Recent clinical data validated KAT6 as a targetable mechanism in the treatment of HR+/HER2- breast cancer, including those with actionable mutations," stated Charles Morris, MBChB, MRCP, Chief Medical Officer
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-06-09 | Sandor Victor | +38,000 | - | - |
| 2026-06-09 | Dorton Katina | +38,000 | - | - |
| 2026-06-09 | Bonita David P | +38,000 | - | - |
| 2026-06-09 | Babler Martin | +38,000 | - | - |
| 2026-06-09 | FRIEDMAN PAUL A | +38,000 | - | - |
| 2026-06-09 | BAKER JULIAN | +38,000 | - | - |
| 2026-06-09 | BAKER JULIAN | +38,000 | - | - |
| 2026-05-01 | Morris Charles Q | +450,000 | $4.7 | $2,115,000 |
| 2026-04-27 | RA Capital Healthcare Fund LP | +1,407,000 | - | - |
| 2026-04-27 | RA Capital Healthcare Fund LP | -1,407,000 | - | - |
| 2026-04-21 | Bonita David P | +1,126,126 | $4.44 | $4,999,999 |
| 2026-04-21 | Bonita David P | +1,689,189 | $4.44 | $7,499,999 |
| 2026-04-21 | ORBIMED ADVISORS LLC | +1,126,126 | $4.44 | $4,999,999 |
| 2026-04-21 | ORBIMED ADVISORS LLC | +1,689,189 | $4.44 | $7,499,999 |
| 2026-04-21 | BAKER JULIAN | +2,137,651 | $4.4399 | $9,490,957 |
| 2026-04-21 | BAKER JULIAN | +114,601 | $4.4399 | $508,817 |
| 2026-02-04 | Combs Andrew | +230,000 | - | - |
| 2026-02-04 | Vaddi Krishna | +837,000 | - | - |
| 2026-02-04 | Scherle Peggy | +230,000 | - | - |
| 2026-02-04 | Lim Bryant David | +275,000 | - | - |
| 2025-11-05 | Sandor Victor | +121,285 | - | - |
| 2025-10-17 | Dorton Katina | +76,000 | - | - |
| 2025-10-04 | Huang Jane | -9,375 | - | - |
| 2025-10-04 | Huang Jane | -3,355 | $1.47 | $4,932 |
| 2025-10-04 | Huang Jane | +9,375 | - | - |